文献速递头颈与中枢神经肿瘤

紫杉醇、顺铂和卡培他滨对比顺铂和氟尿嘧啶诱导化疗对IVA至IVB期鼻咽癌患者无失败生存的影响:多中心3期随机临床试验

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项多中心3期随机临床试验纳入238例IVA至IVB期鼻咽癌患者,随机接受TPC或PF方案诱导化疗后同步放化疗。TPC组3年无失败生存率为83.5%,PF组为68.9%,分层HR为0.47,TPC组远处转移和局部区域复发风险显著降低,但早期总生存无显著差异,毒性未增加。

要点

  • TPC组3年无失败生存率为83.5%,PF组为68.9%(分层HR 0.47,95%CI 0.28-0.79,P=0.004)。
  • TPC组远处转移风险显著降低(分层HR 0.49,95%CI 0.24-0.98,P=0.04),局部区域复发风险显著降低(分层HR 0.40,95%CI 0.18-0.93,P=0.03)。
  • 早期总生存无显著差异(分层HR 0.45,95%CI 0.17-1.18,P=0.10)。

核心结论

  • 对于IVA至IVB期鼻咽癌患者,2周期TPC诱导化疗对比2周期PF诱导化疗改善了无失败生存,且毒性特征未增加。

研究设计与样本

  • 随机、开放标签、3期临床试验,2016年10月20日至2019年8月29日在中国4家医院招募238例患者。
  • 患者年龄18至65岁,为初治非角化性IVA至IVB期鼻咽癌,ECOG体能状态评分为0至1。
  • 患者按1:1随机分配接受2周期TPC或PF诱导化疗,随后接受同步放化疗。

主要发现

  • 238例合格患者(187例男性[78.6%];中位年龄45岁[范围18-65岁])随机接受TPC(n=118)或PF(n=120)。
  • 中位随访时间为48.4个月(IQR 39.6-53.3个月)。
  • TPC组3年无失败生存率为83.5%(95%CI 77.0%-90.6%),PF组为68.9%(95%CI 61.1%-77.8%),分层HR为0.47(95%CI 0.28-0.79;P=0.004)。
  • TPC组对比PF组,远处转移风险显著降低(分层HR 0.49 [95%CI 0.24-0.98];P=0.04),局部区域复发风险显著降低(分层HR 0.40 [95%CI 0.18-0.93];P=0.03)。
  • 早期总生存无显著差异(分层HR 0.45 [95%CI 0.17-1.18];P=0.10)。

关键数值与推荐

  • TPC方案:静脉紫杉醇150 mg/m²第1天,静脉顺铂60 mg/m²第1天,口服卡培他滨1000 mg/m²每日两次第1-14天,每21天为一周期,共2周期。
  • PF方案:静脉顺铂100 mg/m²第1天,氟尿嘧啶800 mg/m²每日第1-5天,每21天为一周期,共2周期。
  • TPC组3至4级急性不良事件发生率为57.6%(n=68),迟发性毒性发生率为13.6%(16/118);PF组分别为65.8%(n=79)和17.9%(21/117)。
  • PF组发生1例治疗相关死亡。

临床怎么用

  • 对于IVA至IVB期鼻咽癌患者,2周期TPC诱导化疗相比2周期PF诱导化疗改善了无失败生存,且毒性未增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear. OBJECTIVE: To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, phase 3 clinical trial recruited 238 patients at 4 hospitals in China from October 20, 2016, to August 29, 2019. Patients were 18 to 65 years of age with treatment-naive, nonkeratinizing stage IVA to IVB nasopharyngeal carcinoma and an Eastern Cooperative Oncology Group performance status of 0 to 1. INTERVENTIONS: Patients were randomly assigned (1:1) to receive induction chemotherapy with two 21-day cycles of TPC (intravenous paclitaxel [150 mg/m2, day 1], intravenous cisplatin [60 mg/m2, day 1], and oral capecitabine [1000 mg/m2 orally twice daily, days 1-14]) or PF (intravenous cisplatin [100 mg/m2, day 1] and fluorouracil [800 mg/m2 daily, days 1-5]), followed by chemoradiotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was failure-free survival in the intention-to-treat population. Secondary end points included distant metastasis-free survival, locoregional relapse-free survival, overall survival, tumor response, and safety. RESULTS: Overall, 238 eligible patients (187 men [78.6%]; median age, 45 years [range, 18-65 years]) were randomly assigned to receive TPC (n = 118) or PF (n = 120). The median follow-up duration was 48.4 months (IQR, 39.6-53.3 months). Failure-free survival at 3 years was 83.5% (95% CI, 77.0%-90.6%) in the TPC group and 68.9% (95% CI, 61.1%-77.8%) in the PF group (stratified hazard ratio [HR] for recurrence or death, 0.47; 95% CI, 0.28-0.79; P = .004). Induction with the TPC regimen resulted in a significant reduction in the risk of distant metastases (stratified HR, 0.49 [95% CI, 0.24-0.98]; P = .04) and locoregional recurrence (stratified HR, 0.40 [95% CI, 0.18-0.93]; P = .03) compared with the PF regimen. However, there was no effect on early overall survival (stratified HR, 0.45 [95% CI, 0.17-1.18]; P = .10). The incidences of grade 3 to 4 acute adverse events and late-onset toxicities were 57.6% (n = 68) and 13.6% (16 of 118), respectively, in the TPC group and 65.8% (n = 79) and 17.9% (21 of 117), respectively, in the PF group. One treatment-related death occurred in the PF group. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that induction chemotherapy with 2 cycles of TPC for patients with stage IVA to IVB nasopharyngeal carcinoma improved failure-free survival compared with 2 cycles of PF, with no increase in the toxicity profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02940925.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li WZ, Lv X, Hu D, et al. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35323856. doi:10.1001/jamaoncol.2022.0122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。